Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arrowhead Pharmaceuticals's revenue for the
three
months ended in Jun. 2026 was MXN1,313 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was MXN12,102 Mil.
Arrowhead Pharmaceuticals's Revenue per Share for the
three
months ended in Jun. 2026 was MXN9.16.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN86.41.
Warning Sign:
Arrowhead Pharmaceuticals Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Arrowhead Pharmaceuticals was 12.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 39.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -4.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 61.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Arrowhead Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 729.50% per year. The lowest was -75.00% per year. And the median was 4.10% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arrowhead Pharmaceuticals Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where Arrowhead Pharmaceuticals's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN12,102 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals (MEX:ARWR) has a Revenue of MXN12,102 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Revenue too high?
Arrowhead Pharmaceuticals' current Revenue is MXN12,102 Mil. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Revenue compare to AXSM and MDGL?
Arrowhead Pharmaceuticals' Revenue of MXN12,102 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Revenue is MXN12,102 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Arrowhead Pharmaceuticals (MEX:ARWR) has a current Revenue of MXN12,102 Mil. The stock's GF Value™ is MXN315.53, compared to a current price of MXN454.55 — trading 44.1% above its estimated fair value. The current Revenue is MXN12,102 Mil. Arrowhead Pharmaceuticals' overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (MEX:ARWR), the current Revenue is MXN12,102 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arrowhead Pharmaceuticals (MEX:ARWR) Overvalued in 2026?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN454.55 is trading 44.1% above its estimated GF Value™ of MXN315.53.
Key valuation signals for MEX:ARWR:
Revenue: MXN12,102 Mil
GF Value™: MXN315.53 vs. price of MXN454.55 (44.1% above fair value)
No single metric tells the full story. See the MEX:ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
45GF Score
Get the complete analysis for MEX:ARWR
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ARWR has been successfully added to your 
